A special session sanctioned by the WHO at this year’s European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) will ask how many more warnings the world needs before it is too late to address the growing threat of antimicrobial resistance (AMR). which increases in all areas of medicine.
A panel that includes England’s former medical director, Professor Dame Sally Davies (now UK special envoy to AMR), will examine the little progress made in recent years despite multiple calls for action and warnings from ‘an antibiotic apocalypse that threatened all the modern medicine we depend on it for daily life.
“Time and time again, alarms have sounded for the broken antibiotic market. Compared to the $ 8 billion in cancer drug profits, the $ 100 million loss for antimicrobials means our cabinets of drugs become more empty, due to failures and not to a lack of scientific intellectual capacity. “, explains Dame Sally. “As it stands, the weak market and lack of access leaves patients paying future generations he will suffer even more. “
According to her, this trend is not sustainable, especially when COVID-19 shows the number of patients who are globally dependent on scientific innovation. “I’ve been saying ‘there’s no time to wait,’ but for many it’s too late: they’re dead. Unless we act now, alarms will soon become the cry of modern medicine,” says Dame Sally .
With more innovation, experts believe AMR can be contained. Last month, the G7 nations pledged to strengthen research and development new antibiotics. In the United States, the PASTEUR Act (which is pending vote by the U.S. House of Representatives and Congress) represents a game-changing mechanism for “attracting” new antibiotics to reach patients who need them most.
The hope offered by the PASTEUR Act is clear: Under this legislation, the U.S. federal government would provide market incentives to develop life-saving antimicrobial drugs. Pharmaceutical / developer companies would be paid contractually agreed amounts annually, for an agreed period of five years until the patent life of the antimicrobial. These contracts would encourage the development of new antimicrobials.
Specifically, these contracts would encourage the development of antimicrobials against the “superbugs” considered most threatening by the U.S. Centers for Disease Control and Prevention (CDC), including Candida auris, a fungus, and bacteria such as Clostridioides difficile and carbapenem-resistant Acinetobacter. . PASTEUR-based contracts would also act as an incentive to develop new classes of antimicrobials with completely new mechanisms of action to reverse these drug-resistant infections.
Meanwhile, the UK has launched a first Netflix-style payment model, which will pay pharmaceutical companies a fixed amount per subscription to access your innovative antibiotic products, rather than fees based on the amount of product used. In December 2020, the UK government selected two antimicrobials: Shionogi’s Fetcroja (Cefiderocol) and Pfizer’s Zavicefta (ceftazidime with avibactam) (Zavicefta), which would be purchased using the Netflix-style subscription payment model. The European Union’s Pharmaceutical Strategy published in 2020 also promises to implement a new “pull” model to further promote the new antimicrobial pipeline that is in difficulty.
Dame Sally concludes, “It is a collective responsibility to ensure that our research and policy making reflects this. From early-stage research to clinical trials to patient access, inclusion must define our innovation. At the global level, we must move forward together, working in collaboration between sectors and countries. ”
Provided by the European Society of Clinical Microbiology and Infectious Diseases
Citation: Antibiotic Resistance: How Many More Final Warnings Before It’s Too Late? (2021, July 9), retrieved July 9, 2021 at https://medicalxpress.com/news/2021-07-antibiotic-resistance-late.html
This document is subject to copyright. Apart from any fair treatment for the purposes of private study or research, no part may be reproduced without written permission. Content is provided for informational purposes only.